

Turkish Alzheimer Prevalence Study

<https://neurodegenerationresearch.eu/survey/turkish-alzheimer-prevalence-study/>

Title of the cohort

Turkish Alzheimer Prevalence Study

Acronym for cohort

Name of Principal Investigator

Title Professor

First name Murat

Last name Emre

Address of institution where award is held

Institution Istanbul University Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit

Street Address Millet Cad. Capa, Sehremini

City Istanbul

Postcode 34093

Country

Turkey

Website

www.itfnoroloji.org

Contact email

bilgicb@gmail.com

Funding source

Pharma industry

1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer's disease and other dementias

When studies on the above condition(s) are expected to become possible

Already possible

2a. Stated aim of the cohort

Prevalence of dementia in Istanbul

2b. Features distinguishing this cohort from other population cohorts

Door to door survey

3a. i) Number of publications that involve use of cohort to date

4

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

3b. Publication list/link to where data or publications are accessible (if available)

3c. Information (i.e. research findings) expected to be gained from the population cohort

4a. Study criteria: age range of participants at recruitment

Age in years from: 70

To ('until death' if applicable): until death

4b. Study criteria: inclusion criteria

Only community dwelling individuals

4c. Study criteria: exclusion criteria

Subjects with severe communication (ie, aphasia or no knowledge of Turkish) and perceptual (ie, deafness or blindness) problems were excluded from the study.

5. Size of the cohort (i.e. number of participants enrolled)

1,000 – 5,000 participants

6a. Measures used to characterise participants

MMSE, neuropsychological evaluation, DSM IV, NINCDS-ADRDA, CDR

6b. Additional measures for participants with a clinical disorder

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

Demented or not

7. Study design

- Prospective cohort
- Cross sectional survey

8. Cases matched by

- Age
- Sex
- Cognitive function

9a. Does the study include a specialised subset of control participants

Yes

9b. If yes, description of specialised subset of control participants

10a. i) Data collection start date

01-10-1999

10a. ii) Data collection end date

10a iii) Data collection for this study is

Closed to new patients

10b. Plans to continue the cohort study beyond the current projected end date

11. Data collected

- Only through the study

12. System in place to enable re-contact with patients for future studies

No

13a. Format and availability of data stored in a database

Yes/No % available

Data summarised in database yes 100

Database is web-based no

Database on spreadsheet yes 100

Database is on paper no

Other (specify)

Language used:

Turkishh and English

13b. Format and availability of data held as individual records

Yes/No % available

Data held as individual records no

Data is web-based no

Data held on computer based records yes 100

Data held on cards no

Other (specify)

Language used:

Turkish and English

14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups

- Apply to PI or co-ordinator at resource

15. Data sharing policy specified as a condition of use

No policy exists

16a. Are tissues/samples/DNA available to other groups

No

16b. i) Description of available tissues/samples/DNA

16b. ii) Form available tissues/samples/DNA are supplied in

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

17. Is information on biological characteristics available to other groups

- No